3 results match your criteria: "Cancer Precision Medicine Uppsala University Uppsala Sweden.[Affiliation]"
Article Synopsis
- Chronic lymphocytic leukemia (CLL) varies greatly among patients, with some experiencing slow progression and others facing aggressive forms leading to early death.
- A study with 1,154 CLL patients examined how lifestyle and medical history factors before diagnosis influenced the time until first treatment (TTFT), adjusting for the CLL-International Prognostic Index (CLL-IPI).
- Results indicated that the CLL-IPI score was the main factor affecting TTFT, with minimal influence from lifestyle factors, providing reassurance to patients about the limited impact of these factors on their disease progression.
Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma - A case report.
EJHaem
August 2024
Department of Immunology Genetics and Pathology, Cancer Precision Medicine Uppsala University Uppsala Sweden.
The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable. However, here we present two cases of life-threatening aplastic anemia (AA) upon treatment with the BTKi acalabrutinib for MCL.
View Article and Find Full Text PDFInfections in patients with mantle cell lymphoma.
Hemasphere
July 2024
Department of Immunology, Genetics and Pathology, Cancer Precision Medicine Uppsala University Uppsala Sweden.
Advancements in treatments have significantly improved the prognosis for mantle cell lymphoma (MCL), and there is a growing population of survivors with an increased susceptibility to infections. We assessed the incidence of infections by clinical characteristics and treatment both before and after MCL diagnosis in Sweden. Patients with a diagnosis of MCL ≥ 18 years between 2007 and 2019 were included, along with up to 10 matched comparators.
View Article and Find Full Text PDF